Claude Farrugia, EIPG Vice-President
Presentation at EIPG – VAPI-UPIP Symposium “Biotech and Advanced Therapies: Challenges and Opportunities” at the Faculty of Medicine and Pharmacy, Campus Jette, Vrije Universiteit van Brussel, Brussels 2013
Aarti Drugs Limited (ADL), incorporated in 1984 is part of Rs 3,000 crore Aarti Group of
Industries and is engaged in manufacturing and sale of Active pharmaceutical ingredients
(APIs), advanced intermediates and specialty chemicals. ADL manufactures drugs in
therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, sedatives,
anti-depressant, anti-diarrhea and anti-inflammatory.
In Aarti Drugs we get a bulk drugs manufacturer with steady growth across the years,
continuously improving performance on various financial parameters, good dividend
yield of more than 5% and low valuations of 5 times earnings and EV/EBIT of 5.28.
Besides, what instills further confidence in the stock is the fact that promoters of the
company have been continuously increasing their stake with regular purchases from open
market. Two years back promoters had 54.83% stake in the company and the same now
stands increased to 59.65%.
Aarti Drugs Limited (ADL), incorporated in 1984 is part of Rs 3,000 crore Aarti Group of
Industries and is engaged in manufacturing and sale of Active pharmaceutical ingredients
(APIs), advanced intermediates and specialty chemicals. ADL manufactures drugs in
therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, sedatives,
anti-depressant, anti-diarrhea and anti-inflammatory.
In Aarti Drugs we get a bulk drugs manufacturer with steady growth across the years,
continuously improving performance on various financial parameters, good dividend
yield of more than 5% and low valuations of 5 times earnings and EV/EBIT of 5.28.
Besides, what instills further confidence in the stock is the fact that promoters of the
company have been continuously increasing their stake with regular purchases from open
market. Two years back promoters had 54.83% stake in the company and the same now
stands increased to 59.65%.
Примечательно, что в 2012 году, во время своей активной деятельности, Микитюк декларировал миллионные доходы, настоящие автопарки личных машин и гектары земли.
Maurizio Battistini, EIPG Vice-President
EIPG Presentation at Pharmaceutical Supply Chains I, a training school organised by Cost Action CA15105: European Medicines Shortages Research Network – addressing supply problems to patients (Medicines Shortages), Lisbon 2017
More Related Content
Similar to Biotech and Advanced Therapies: A Pharma Renaissance
Примечательно, что в 2012 году, во время своей активной деятельности, Микитюк декларировал миллионные доходы, настоящие автопарки личных машин и гектары земли.
Maurizio Battistini, EIPG Vice-President
EIPG Presentation at Pharmaceutical Supply Chains I, a training school organised by Cost Action CA15105: European Medicines Shortages Research Network – addressing supply problems to patients (Medicines Shortages), Lisbon 2017
Claude Farrugia, EIPG President
EIPG Presentation at European Clinical Trial Day, an international conference organised by AFI and Regione Lombardia, endorsed by EIPG, Milan 2017
Claude Farrugia, EIPG Vice-President
EIPG Presentation at VAPI-UPIP Seminar “Implementation of the new Delegated Act on Falsified Medicines”, Limelette 2016.
Prof Kristien De Paepe
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Dr Gavin Halbert
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Prof Clive Badman OBE
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Prof Angela Timoney
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Prof Alastair Florence
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Jean Pierre Paccioni, EIPG President
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
Jacques Morénas, Deputy Director, Inspection Division, ANSM
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
Borislav Borissov, Former Head of BDA
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
Georgina Gal, Regulatory Affairs Manager, AbbVie, Hungary
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
More from European Industrial Pharmacists Group (20)
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
4. .....and pharma is not 'immune~.
TOP 10 COMPANIES
Many big drug companies are
seeing their sales decline
12-MONTH
SALES· CHANGE IN
(S BilliONS) SALES
Pfizer $51.9 -8.6%
Novartis SO.8 2.0
Merck & Co. 40.9 6.8
Sanofi 38.9 -0.9
Roche 35.0 2.7
AstraZeneca 34.5 -5.4
Glaxo$mithKline 33.6 -1.8
Johnson & Johnson 26.8 -4.5
Abbott laboratories 25.8 4.1
Teva 24.0 -3.4
TOTAL $362.2 ·L2%
GLOBAL MARKET $857.3 3.5%
.. For the 12 months ending on June 30. 2012.
SOURCE: IMS Institute 101" Healthcare Inlormahcs
5. .....and pharma is not 'immune'.
PHARMACEUTICAlR&D
EXPENDITURES
$70 billion
NEW DRUGS
APPROVEO·
60
'10'05'00
o
'95
40
30
50
20
PhrMa ..
............i1'le'frlt;4~ffs·'········
10
'95 '00 '05 '09
o
."""",11,.
10-- .... .....
50
40
30
20
60" .
6. .....and pharma is not 'immune'.
6.
5.
-:. 4.Z
-
PhRMA Member
~ Ra.O Sp~djnll
3S
$16.9 $19.0
$15.2
Sl"2.7 $13.4
24
New Drug
AHrov.ts (NME.)
17
"
16
...
...
-•
•• ~
~
•-:l~
E•
•~
••••
• 1992 nu I.M 1995 J996 1997 199. 1999 2000 2001 2002 2003 2004 2005 2006
6.
7. Drug Development: Costly and Lengthy
Number of Compounds to Produce a New Drug
'_IV..- ---_ '_7'1'... --~. _ O.$·~Y.... _
8. Drug Development: Costly and Lengthy
Number of Compounds to Produce a New Drug
,
n m
--
P",
lid •
I
1·7',... ---+.
Pha~lI.
so-~
parienls
$750,000
9moDlbs - ~
)'N1n
-
_---'_l-- _
Phoilse Ib
}o-so hWlhy
subjoKu
5300,000
6monrhs - I
}"~f
._----
Ph.ut'la
40-60 heahb)'
subje<15
S3OO,000
61110111115
r"'-""'''''''"''-''--r .
9. Drug Development: Costly and Lengthy
Number of Compounds to Produce a New Drug
'_IV..- ---_ '_7'1'... ---+. _ O.$·~Y.... _
10-15 yearsfrom start to launch
10. Just to put things in perspective...
-----
------
_. -- --- ----- -
---- ---- ------
_.---:";...-
--
10-15 yearsfrom start to launch
12. The Patent Cliff: A Race Against Time
1,n4
o
2,000
1,000
Annual Sales Volume in the EU
becoming available for competition
2,268
€ million 2,On 2,059
2004 2005 2006 2007 2008 2009 2010
13. The Patent Cliff: A Race Against Time
,.~2
11'
-'-'"
UoMONTH CKAHCL
."""-2.~
-().
-&3
..>7.
-102
.,
"."
••••••
"",,'
($ R.LIOIlS)
.".,B<
.,
",.,.
--H)P!'d~
......-_.Un....d '11.......
-- .Aad ..... dosNwsynptoms
Cn:JM", dlwaw. rtlftmalood a-ttwM
..........
"""'"'"""""""""'..........z-.
AlltlotI Uibcnloroes
"""-'
..........""
TOP 10 PRODUCTS
Sa~ are declining for many of the workfs top pharmaceuUcals
CC, FOIMO
Ch "'-,Nl
-~..........
"""""-........
""'"......."'""X
=...
• ,...I 2 _ - .... _lO.:zoLt SOI*t:US_1OI ~..... •
15. •
The Patent Cliff: A Race Against Time
SOLUTION
Companies offer a mixed portfolio ofnew medicines and..
generic medicines.
• -
HOWEVER
Many originator companies do not possess the experience
and/or know-how to play in the generic space, and must
• acquireorform joint ven,tures with existing players.
PROBLEM
Increased scrutiny from competition watchdogs.
Federal Trade Commission v. Watson Pharmaceuticals Inc et al.,
.... .." U5'Supreme Court
16. Are we prepared to pay?
In Europe, generics make up almost one halfofvolume
sales. but merely a fraction ofvalue sales
,....
",,,
""'
,.,.
"'"
'''''
11 Volume· aeneric market share
70K 10K
17. Are we prepared to pay?
"Europe must ensure that it doesn't slip into
a position where it simply focuses on
acquiring medicines at the lowest possible
cost. This will destroy the incentivisation for
innovation, and will ultimately lead to a loss
ofthe breakthrough opportunities ofnew
medicine research. The importance ofthis
industry to health, healthy ageing, and
economic growth is just too great to run that
. I "rise
(Richard Bergstriim, Director General EFPIA)
18. Are we prepared to pay?
"Europe has unfortunately slipped in terms
ofits willingness to pay for innovation. ...
We're now at a point where we have to take
the view and I think face the reality that
really it's about the U.S. and, excitingly
anew, it's about Japan in terms ofwhere
innovation should be driven."
(Sir AndreIV Witty, CEO ClaxoSmithKline)
19. Where have we heard this before?
NME LAUNCHES
New Mol.cular Entities (NMEs)
by Region of First Launch
203 170
----
• •
/
Europe
1/u.s.
o+-,~~~~~~
9293949596979899000102
20
o
, 993-1997 1998-2002
20. Enter the Global Markets.
Spending by Geography
SI,I]5-I,20S6n
>0"
• United States
·'"'• lllP¥l
• Ph¥merlllng
• Cilllllda
• Rest of Europe
• S(IO,lth Korea
• Rest of Wor1d
21. Enter the Global Markets.
'''' "" INOex
"'"' 2011 INDEX
"'"' 2016 INOEX
, United Slales
""
, United St.l",
'"
, United Stde,
""2 Japan 35 2
~"" " 2 A China
", A fr.nce
"
, A ChilD
"
, V
""" ", V Germany
"
, Germany
"
, A Br.zil
", A Ch;""
• , V france
"
, V Ge'lI'llny
", V It.ly
• , A BIiI.;[
• , V Fr.n<:t
", A Spain , , V Italy
• ,
'""
,
, V
"'
, • V Spain , , A lndia ,
• V ~.~
, • C.nada , • A Russia ,
" Brazil 5
" V
"'
,
" V C.n.d. ,
" AlI$t"li.l , " A Russia ,
" V
"'
,
" Mexico , " V Au,tuli. ,
" V Sp.lin 5
" South Ko... , " A India ,
" V Australi. ,
" Russia , " V Sootll Kore. , " A Argenti". ,
" V lodi. 2
" V Mexico , " V South Ko,e. ,
" A Turkey 2
" Turkey , " V Mel<ko ,
" V Nethe,wnds 2
" A ~.~ 2
" A VeneZllela ,
18 V 8l'lgium 2 18 A Venezuela 2 18 V Turkey ,
" A Gr_e 2
" V Netherl,""l$ 2
" A lndo~ia 2
" V
"'.~
2
" V Bolgium 2
" V "'.cd 2
........ Change in r.nking OVI!f prior 5 ye."
ApP'tndi. noles
R,nk;'"') in an y"" b.<ed on ....od;"'I in ,,,,,,tonl US!.I Q< l{)ll u,h."9I' ..tu.
Sourct: [MS ""'.1<<1 Progno'i'. ""'I' 2012 I"m in "ch 'I'" too," on "tio of country .....din9 to U.S. ,pendiog (in con,unt US,) in the y..'.
22. Enter the Global Markets.
w, 50'"z
• "''''•, 50'"
•~ so",
~ .,'"~ .,'"9 ,.'"0
~
"'"w
«
'"'•z
•
•
Global New Molecular Entities
Country Availability
Pharmerging
I
I I
• Additional 2006-2010 NME avallat>~ In 2016
.2006-2010 NME available In 2011
Sou"",: DlS In<titIIu for Htalthr.o.. lnb....tic.. May lOll
23. Global markets are not European
• Diverse healthcare systems
• Fragmented markets
• Complex regulatory systems
• Cultural and language barriers
• Increased competition (local and global)
• Varied infrastructure
• Highly dynamic situation
24. Global markets are not European
Figure 2: Tne Wealth Pyramid across the emerging markets (adapted from Praflalad and
Ueberthal, 19981),
PlJrdlaslng power parity Population in millons
In U.S. doILn Chi" ..... ...",
B Greatel'" than S20,OOO 2 7
•
How
S10,000 to S20.000 60 63 15
H..... "'"
SS.COO to S10,000 m 125 27
/ _not le,st•.,,,,OOO 800 700 105
25. Global markets are not European
2016 PharmaceuticaL Spend Per Capita
2005S and Population
(hlno ,'U Plop. '.)<19.....
""""""'!ling lie, J '96 I'bp. 1.012""
I...... Ul Pop. 1,192.....
~--U5. '892 Pop.3Z6Mn
JI.-n $6«4 I'q). U ......
c...lo '420 !'<>p. J6Mn
EU5 $375 ,..,.., 320Mn
_ _ un !'<>p. SOHn " ~=,
!
!leS' 01 Eun>pe pn "",,1_ I
BrOlW "eo Pop. 20''''
R..... '179 ""p. 140Hn
•
~
.~
o
~700
~~
o~
~
3'00
~~
l~
• '00
-,~
Vletnam
• .~.~..N
N
-•
~ - 1lr1I,;1
.~ ,-~
,~.
- ,-,w ,,-
~
,~
~~"". .-~el_si.
> ,~
• • ~.~
~
"~, • ThllII"Cl MoleO••
-,~
b
~ ,~ .~
- - ,-.. ~ POPIJI..,I,T10N wrrn 2016 INCOI'lE >15,000
I Volume Growth and Populations
I With >S5,OOOjYear Income by Country in 2016
26. Global markets are not European
Intellectual Property
• Indian patent law allows for compulsory licensing if
"reasonable requirements of the public with respect to
the patented invention have not been satisfied; the
patented invention is not available to the public at a
reasonably affordable price; or the patented invention
has not been worked in the territory ofIndia".
• 2012: Indian patent office authorised Natco Pharma to
make and sell generic sorafenib (Nexavar, Bayer AG)
whilst still under patent, paying 'fA> of its net (reduced)
sale in royalties to Bayer.
• Trastuzumab (Herceptin, Roche), ixabepilone and
dasatinib (Ixempra and Sprycel , Bristol-Myers Squibb)
under consideration.
27. Global markets are not European
Price control:
• China: In 2013 cut prices of more than 400
medicines by up to 20%.
• India: In 2012 widened scope of price controls to
348 medicines from 74. In 2013, proposes that
prices of patented medicines be based on the
country's per capita income.
• "Most countries follow some form ofprice control.
We need to ensure that expensive drugs are
available at affordable rates to the poor.n
(D.S. Kalba, Secretary, Pharmaceutical Department)
28. Global markets are not European
"The danger ofpushing the prices
ofprescription drugs down, down,
down is that at some point the
business model of developing
these drugs will lose its
attractiveness. India is
becoming very reluctant to
respect IP for Western companies
and that is becoming a challenge
for us."
(Marijn De""ers, CEO Bayer)
29. Global markets are not European
Global Spending, 2011 aocl 2016
r
Pharmerging Spending and Growth
••
•
.--
•••
.--
""
_.""_...,
_.......-.. . ~
000';'
_","_"__ W_.-.-,,",'" _ ... _ ... _ _ IJli _ _ .......
30. '[J@
Changes in the industry: a renaissance
"1 really believe that in the jilture,
companies like Novartis are going
to be paid on patient outcomes as
opposed to selling the pill. ... Many
health-care systems around the
world are under intense financial
pressure and would prefer to pay
for a patient who is actually
getting a result and feeling better.
... The industry needs to spend
more money on R&D and less on
sales and marketing."
(joseph jimenez, CEO Novartis)
31. Changes in the industry: a renaissance
r
Spending and (j,owth in leading Therapy Areas Spending in 2016
----~
w_
w·_
.n-~
w·_
,,~
"...-.,J.._
.~
"...-....,-.....-.,,-"......,,)0,_
.u-,_.Uo,_
.
--
_:IlI_.....__
.-:l
<
--• •
--_ 10 _
-----_s ---
--
-"._.._-.......
-lu
f-"-.-::::...--...
_ .......... f;,IGR
_ ~U·lOl6 ~
.,. - "' -SI'OCIING ~ lOll·lOlI
-.,M_..__.......
32. Changes in the industry: a renaissance
Biosimilar penetration in Europe embryonic;
potential in USA post 2014
For R&D based companies is going to be an established market play
,..-
-.- •
Zl....
>~
~:..-~
<~
...-
.-.-
-.-
•
33. '[J@
Changes in the industry: a renaissance
''It's not like engineering where the
iPhone 5 follows on ji-om the iPhone 4.
Coming up with a new drug requires skill,
insight and luck. .... But we are on the
verge, potentially, ofa new wave of
pharmaceutical innovation."
(Kenneth Frazier, CEO Mere" & Co)
34. European industrial pharmacists
Q12013: Annus horribilis
• GSK to close financial services operations in Cork (Ireland), 94 jobs to
go
• MSD to close facility in Rathdrum (Ireland); 280 jobs to go
• Actavis Malta to close R&D unit by end 2013; 64 jobs to go
• AstraZeneca to close Aiderly Park (UK), overhaul R&D, cut about 1,600
jobs; 2.300 job cuts in sales and adnlinistration; total of 5,050 jobs by
2016
• Eli Lilly to layoff 1,000 US sales jobs
• TEVA to reduce manufacturing footprint, job losses in Israel likely over
next five years
• AbbVie to fire mid-hundreds of sales force for heart drugs
35. European industrial pharmacists
• A changing workplace:
• drug discovery in Europe, drug development and
commercialisation in far East, registration and
marketing in Europe or North America
• drug discovery, development and commercialisation in
far East, and then registered and marketed in Europe
• Logistical challenges to avoid shortages of supply
• Challenges to safeguard quality, safety and efficacy
• Temperature control of biologicals in transportation
• Falsified medicinal products
36. Falsified Medicinal Products
I 2008 2009 I 2010 I 2011
Numberofcases 3.2 °7 3>368 1,812 2,494
Numberofarticles 8,891,°56 11,462,533 3,200,492 27,460,538
India UAE India China
(51.6%) (73-7%) (93.2%) (68.2%)
ProvenanceTop 3
Syria India China India
(36.4%) (22.6%) (4-7%) (28.2%)
UAE China Hong Kong Hong Kong
(8:7"10) (1.4%) (0·9%) (1.5%)
European Commission Taxation and Customs Union
37. European industrial pharmacists
Seven Skill Sets Necessary to Operate in the Pharmaceutical
Industry of the Future
1) Ability to Manage Decentralized Intellectual Capital Resources
2} Ability to Work In Joint Ventures and Across Divisions. Cultures and Countries
3) Abflity to Integrate an Understanding of Intellectual Property laws.
Scientific Expertise and Business Strategy
4) Ability to Spur Creativity While Managing Commercially
5) Knowledge and Insight on the Decision-Making Dynamics of Payers
6) Expertise In the Functioning and Decision-Making of Regulatory Agencies
7) Human Resource Skills to Help Transform Pharmaceutical Companies
38. C:European Industrial Pharmacists Group
• The main objective of EIPG is to promote and uphold
the importance and role of the industrial pharmacist
within the pharmaceutical industry.
• Promote the modern pharmaceutical industry to
observers and more importantly to young pharmacists
• Ensure that educational standards meet the needs of the
industrial pharmacist in the industry of 2020
• Provide mentoring and coaching to young pharmacists
who need career advice
40. {{Former/~ when religion was strong
and science weak, men mistook magic
for medicine; noL1f, when science is
strong and religion weak, men mistake
medicinefor magic."
Thomas Szasz